|
| |
 |
| |
|
| |
| Latest News |
Data Presented From Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
>>more
|
Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients
>>more
|
Lilly Names New Business Leaders
>>more
|
|
|
|
 |
| |
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE:LLY), is committed to advancing oncology
care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with
a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology.
Beyond its marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various
stages of clinical development. ImClone's research and clinical development capabilities
are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art
FDA-approved manufacturing facilities provide it with one of the largest biologic manufacturing capacities in the world.
ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company on November 24, 2008. Read the press release
Additional information about Lilly is available at www.lilly.com
|
|
